Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
3.040
-0.330 (-9.79%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for ALLO stock have an average target of 15.39, with a low estimate of 7.00 and a high estimate of 35. The average target predicts an increase of 406.25% from the current stock price of 3.04.
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2024.
Analyst Ratings
The average analyst rating for ALLO stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 5 | 5 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 5 | 5 | 4 | 3 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 14 | 14 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +228.95% | Mar 19, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +228.95% | Mar 15, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +163.16% | Feb 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +228.95% | Jan 19, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 5, 2024 |
Financial Forecast
Revenue This Year
41.14K
from 95.00K
Decreased by -56.70%
Revenue Next Year
6.93M
from 41.14K
Increased by 16,748.74%
EPS This Year
-1.69
from -2.09
EPS Next Year
-1.57
from -1.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 210,000 | 64.0M | 163.8M | 528.0M | 1.3B |
| Avg | 41,137 | 6.9M | 49.7M | 312.1M | 700.1M |
| Low | n/a | n/a | n/a | 176.6M | 479.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 121.1% | 155,518.1% | 2,263.2% | 961.5% | 325.5% |
| Avg | -56.7% | 16,748.7% | 617.7% | 527.5% | 124.3% |
| Low | - | - | - | 255.0% | 53.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.96 | -0.25 | -1.23 | -0.28 | 1.31 |
| Avg | -1.69 | -1.57 | -1.72 | -0.85 | 0.39 |
| Low | -2.06 | -2.16 | -2.39 | -1.76 | -0.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.